+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Pharmacogenomics Market by Therapeutic Area, Product, Technology, End User, Test Type, Biomarker Type - Global Forecast to 2030- Product Image
Pharmacogenomics Market by Therapeutic Area, Product, Technology, End User, Test Type, Biomarker Type - Global Forecast to 2030- Product Image
Sale

Pharmacogenomics Market by Therapeutic Area, Product, Technology, End User, Test Type, Biomarker Type - Global Forecast to 2030

  • PDF Icon

    Report

  • 198 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5716074
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Pharmacogenomics Market grew from USD 4.48 billion in 2024 to USD 4.98 billion in 2025. It is expected to continue growing at a CAGR of 10.59%, reaching USD 8.21 billion by 2030.

Shaping the Future of Personalized Medicine Through Pharmacogenomics

Pharmacogenomics lies at the forefront of the personalized medicine revolution, unlocking the potential to tailor therapies according to individual genetic profiles. By integrating genomic data into drug development and clinical decision making, this discipline promises to enhance treatment efficacy, reduce adverse reactions, and streamline clinical workflows. The rapid evolution of genomic technologies, coupled with the maturation of data analytics, has transformed pharmacogenomics from a niche research field into a strategic priority for biopharmaceutical firms, diagnostic laboratories, and healthcare providers.

This executive summary distills the most salient insights shaping the pharmacogenomics market today. It illuminates the transformative forces driving adoption, examines the implications of forthcoming tariff adjustments in the United States, and uncovers granular segmentation and regional dynamics. Additionally, it highlights competitive strategies deployed by leading innovators and delivers actionable recommendations for industry leaders. Underpinned by a comprehensive research framework, this analysis equips decision makers with the clarity needed to navigate a complex landscape, optimize investments, and harness the full potential of genomic-driven therapeutics.

Emerging Dynamics Reshaping the Pharmacogenomics Landscape

The pharmacogenomics landscape has undergone a fundamental shift, fueled by breakthroughs in next-generation sequencing and real-time analytics platforms. Innovative molecular assays now offer unprecedented sensitivity and throughput, enabling laboratories to deliver rapid, cost-effective genotyping and phenotyping services. Simultaneously, the integration of artificial intelligence and machine learning into data interpretation has accelerated the translation of genomic insights into clinical action, empowering physicians to prescribe therapies with a higher probability of success.

Regulatory bodies worldwide have begun to codify guidelines for the incorporation of pharmacogenomic markers into clinical practice, signaling a maturation of the field. Collaborative alliances between technology providers, contract research organizations, and academic centers have expanded the scope of clinical trials, embedding genomic stratification into study protocols. As reimbursement frameworks evolve to recognize the economic value of precision prescribing, the alignment of payer incentives with patient outcomes is fostering broader market acceptance. This convergence of technological, regulatory, and economic drivers is redefining the contours of personalized medicine.

Navigating the Effects of US Tariff Adjustments on Pharmacogenomics

Anticipated adjustments to United States import tariffs in 2025 are poised to exert a significant influence on the pharmacogenomics market. Elevated duties on specialized sequencing instruments, reagents, and assay kits may drive up operational expenses for diagnostic laboratories and clinical service providers. In response, manufacturers are exploring supply chain diversification, seeking alternative sourcing from allied trading partners to mitigate cost pressures. At the same time, value-based contracts and long-term procurement agreements are emerging as strategic tools to stabilize pricing and ensure continuity of supply.

While some cost burden is likely to be passed downstream, innovative financing models and bundled service offerings can cushion end users against sudden price hikes. Forward-thinking organizations are leveraging localized manufacturing and strategic partnerships with reagent suppliers to maintain margin integrity. Continuous monitoring of policy developments and proactive engagement with trade authorities will prove essential for industry participants to anticipate regulatory shifts and preserve competitive advantage. Ultimately, agile adaptation to the evolving tariff environment will determine which stakeholders can sustain growth in a more complex global marketplace.

Unlocking Market Nuances Through Detailed Segmentation Insights

Market segmentation reveals the multifaceted drivers shaping pharmacogenomics adoption across therapeutic areas, products, technologies, end users, test types, and biomarker categories. Within the realm of therapeutic focus, oncology commands the greatest investment as targeted therapies increasingly depend on precise somatic mutation profiling. Neurology follows as researchers seek genetic markers for neurodegenerative diseases, while infectious disease applications leverage genotyping to predict drug resistance and personalize antiviral regimens. Cardiology maintains steady demand driven by warfarin dosing algorithms and emerging polymorphism studies.

Product segmentation underscores the pivotal role of consumables, particularly kits and reagents designed for high-throughput workflows. These modular components empower laboratories to customize panels and adapt to evolving assay requirements. Services continue to expand, with clinical services bridging patient diagnosis and treatment optimization, and research services underpinning drug development pipelines. Software and platforms have surged in importance, as data analysis suites, e-clinical solutions, and reporting and interpretation tools provide the connective tissue between raw genomic data and actionable insights.

The technology landscape itself is defined by sequencing, polymerase chain reaction, and microarray modalities. Next-generation sequencing spearheads broad-spectrum mutation detection, while Sanger sequencing retains relevance for targeted validation. Real-time and digital PCR deliver rapid quantification for known variants, and microarrays-ranging from expression arrays to SNP arrays-remain a cost-effective option for specific gene expression studies. End users span hospital-based and reference diagnostic laboratories, hospitals integrating precision protocols, pharmaceutical companies embedding genomic stratification into clinical trials, and research organizations driving innovation. Genotyping dominates test volumes, but phenotyping assays are gaining traction in complex trait evaluations. Finally, germline biomarker assays lead predictive screening efforts, while somatic testing is indispensable for precision oncology.

Regional Dynamics Driving Pharmacogenomics Market Expansion

Regional analysis illuminates distinct growth trajectories across the Americas, EMEA, and Asia-Pacific. In the Americas, robust infrastructure and favorable reimbursement policies have established the United States as a global pharmacogenomics leader. Canada and Latin America show measured expansion, fueled by strategic partnerships and targeted pilot programs that validate pharmacogenomic utility.

Europe’s regulatory harmonization under the In Vitro Diagnostic Regulation has bolstered market confidence, especially in major economies such as Germany, the United Kingdom, and France. Emerging markets in the Middle East and Africa are leveraging public-private collaborations to build genomic testing capabilities, with investments in laboratory accreditation and workforce training accelerating adoption.

Asia-Pacific presents the fastest growth potential, propelled by investments in biotechnology hubs across China, Japan, South Korea, and India. National precision medicine initiatives are driving large-scale genomic projects, while improving healthcare infrastructure is creating pathways for commercial assay deployment. Tailored strategies that address regional regulatory requirements and healthcare reimbursement structures will be critical to capitalize on these diverse opportunities.

Leader Strategies Defining the Competitive Pharmacogenomics Arena

Leading companies are forging strategic pathways to secure market share in pharmacogenomics. Sequencing pioneers have broadened their portfolios to include end-to-end solutions, encompassing sample preparation, instrument platforms, and bioinformatics pipelines. Instrument manufacturers are collaborating with reagent suppliers to deliver optimized kits that ensure assay reliability and reproducibility. Concurrently, software developers are integrating artificial intelligence capabilities to automate variant interpretation, reducing time to result and increasing clinical confidence.

Service providers have established centers of excellence to support both clinical trials and diagnostic testing, offering comprehensive project management and quality assurance. Partnerships between diagnostic firms and pharmaceutical companies are expanding companion diagnostic programs, enabling co-development of targeted therapies. In parallel, contract research organizations are investing in proprietary biomarker discovery platforms to differentiate their offerings. This strategic mosaic of alliances, platform integrations, and service enhancements exemplifies how established and emerging players are positioning themselves for sustained leadership.

Strategic Imperatives for Driving Market Leadership in Pharmacogenomics

Industry leaders must pursue strategic imperatives to navigate evolving market complexities. First, they should invest in scalable next-generation sequencing infrastructure, ensuring flexibility to address both broad-panel and targeted testing needs. Second, diversifying procurement channels through regional manufacturing partnerships will mitigate tariff volatility and logistical risks. Third, integrating advanced analytics and AI-driven interpretation platforms will accelerate clinical adoption by simplifying data insights for end users.

Furthermore, forging collaborative alliances with healthcare systems, contract research organizations, and biopharmaceutical developers will create synergistic value chains that drive test volume and market penetration. Developing tiered service models that align pricing with clinical impact can facilitate broader reimbursement acceptance. Finally, dedicating resources to regulatory intelligence and advocacy will empower organizations to anticipate policy changes, shape industry standards, and secure a competitive edge in a rapidly evolving landscape.

Robust Research Framework Ensuring Insight Accuracy

This analysis is grounded in a rigorous research methodology that blends secondary and primary data sources to ensure reliability and depth. Secondary research encompassed a thorough review of scientific literature, industry publications, regulatory filings, and company disclosures to map technological trends and regulatory developments. Publicly available databases provided insights into clinical trials, patent landscapes, and reimbursement policies across key regions.

Primary research involved structured interviews and dialogues with thought leaders, including genomic scientists, laboratory directors, clinical oncologists, pharmaceutical executives, and policy experts. These interactions validated market trajectories, challenged assumptions, and surfaced emerging use cases. Data triangulation was applied throughout the process, cross-referencing quantitative metrics with qualitative insights to refine the analysis. A layered validation approach, including peer review by domain specialists, ensures that the findings and recommendations presented here reflect the highest standards of accuracy and relevance.

Consolidating Insights to Guide Strategic Decisions

The pharmacogenomics market stands at a critical juncture, propelled by technological innovation, evolving regulatory landscapes, and shifting economic incentives. As the discipline transitions from early adoption to mainstream integration, stakeholders must remain vigilant to external pressures such as tariff adjustments and regional policy variations. By understanding the nuanced segmentation, competitive strategies, and geographic dynamics outlined herein, decision makers can craft forward-looking strategies that advance personalized medicine and deliver tangible patient value.

The insights and recommendations offered in this executive summary serve as a strategic compass for organizations seeking to harness the full potential of genomic-driven therapeutics. In an environment defined by rapid change, proactive adaptation and collaborative engagement will determine which entities lead the next wave of innovation in pharmacogenomics.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Therapeutic Area
    • Cardiology
    • Infectious Diseases
    • Neurology
    • Oncology
  • Product
    • Consumables
      • Kits
      • Reagents
    • Services
      • Clinical Services
      • Research Services
    • Software And Platforms
      • Data Analysis
      • E-Clinical Solutions
      • Reporting And Interpretation
  • Technology
    • Microarray
      • Expression Arrays
      • SNP Arrays
    • Polymerase Chain Reaction
      • Digital PCR
      • Real-Time PCR
    • Sequencing
      • Next-Generation Sequencing
      • Sanger Sequencing
  • End User
    • Diagnostic Laboratories
      • Hospital-Based Laboratories
      • Reference Laboratories
    • Hospitals
    • Pharmaceutical Companies
    • Research Organizations
  • Test Type
    • Genotyping
    • Phenotyping
  • Biomarker Type
    • Germline
    • Somatic
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Thermo Fisher Scientific Inc.
  • Illumina, Inc.
  • F. Hoffmann-La Roche Ltd
  • QIAGEN N.V.
  • PerkinElmer, Inc.
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • Myriad Genetics, Inc.
  • Invitae Corporation
  • Natera, Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Pharmacogenomics Market, by Therapeutic Area
8.1. Introduction
8.2. Cardiology
8.3. Infectious Diseases
8.4. Neurology
8.5. Oncology
9. Pharmacogenomics Market, by Product
9.1. Introduction
9.2. Consumables
9.2.1. Kits
9.2.2. Reagents
9.3. Services
9.3.1. Clinical Services
9.3.2. Research Services
9.4. Software and Platforms
9.4.1. Data Analysis
9.4.2. E-Clinical Solutions
9.4.3. Reporting and Interpretation
10. Pharmacogenomics Market, by Technology
10.1. Introduction
10.2. Microarray
10.2.1. Expression Arrays
10.2.2. SNP Arrays
10.3. Polymerase Chain Reaction
10.3.1. Digital PCR
10.3.2. Real-Time PCR
10.4. Sequencing
10.4.1. Next-Generation Sequencing
10.4.2. Sanger Sequencing
11. Pharmacogenomics Market, by End User
11.1. Introduction
11.2. Diagnostic Laboratories
11.2.1. Hospital-Based Laboratories
11.2.2. Reference Laboratories
11.3. Hospitals
11.4. Pharmaceutical Companies
11.5. Research Organizations
12. Pharmacogenomics Market, by Test Type
12.1. Introduction
12.2. Genotyping
12.3. Phenotyping
13. Pharmacogenomics Market, by Biomarker Type
13.1. Introduction
13.2. Germline
13.3. Somatic
14. Americas Pharmacogenomics Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Pharmacogenomics Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Pharmacogenomics Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Thermo Fisher Scientific Inc.
17.3.2. Illumina, Inc.
17.3.3. F. Hoffmann-La Roche Ltd
17.3.4. QIAGEN N.V.
17.3.5. PerkinElmer, Inc.
17.3.6. Agilent Technologies, Inc.
17.3.7. Bio-Rad Laboratories, Inc.
17.3.8. Myriad Genetics, Inc.
17.3.9. Invitae Corporation
17.3.10. Natera, Inc.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. PHARMACOGENOMICS MARKET MULTI-CURRENCY
FIGURE 2. PHARMACOGENOMICS MARKET MULTI-LANGUAGE
FIGURE 3. PHARMACOGENOMICS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2030 (%)
FIGURE 8. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2024 VS 2030 (%)
FIGURE 10. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 12. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY TEST TYPE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY BIOMARKER TYPE, 2024 VS 2030 (%)
FIGURE 18. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY BIOMARKER TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. PHARMACOGENOMICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. PHARMACOGENOMICS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. PHARMACOGENOMICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY KITS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY REAGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY SERVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY CLINICAL SERVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY RESEARCH SERVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY SOFTWARE AND PLATFORMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY DATA ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY E-CLINICAL SOLUTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY REPORTING AND INTERPRETATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY SOFTWARE AND PLATFORMS, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY EXPRESSION ARRAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY SNP ARRAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY MICROARRAY, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY REAL-TIME PCR, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY SEQUENCING, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY HOSPITAL-BASED LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY GENOTYPING, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY PHENOTYPING, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY GERMLINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY SOMATIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY SOFTWARE AND PLATFORMS, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY MICROARRAY, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY SEQUENCING, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY SOFTWARE AND PLATFORMS, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY MICROARRAY, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY SEQUENCING, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 80. CANADA PHARMACOGENOMICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 81. CANADA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 82. CANADA PHARMACOGENOMICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 83. CANADA PHARMACOGENOMICS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 84. CANADA PHARMACOGENOMICS MARKET SIZE, BY SOFTWARE AND PLATFORMS, 2018-2030 (USD MILLION)
TABLE 85. CANADA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 86. CANADA PHARMACOGENOMICS MARKET SIZE, BY MICROARRAY, 2018-2030 (USD MILLION)
TABLE 87. CANADA PHARMACOGENOMICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2030 (USD MILLION)
TABLE 88. CANADA PHARMACOGENOMICS MARKET SIZE, BY SEQUENCING, 2018-2030 (USD MILLION)
TABLE 89. CANADA PHARMACOGENOMICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 90. CANADA PHARMACOGENOMICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 91. CANADA PHARMACOGENOMICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 92. CANADA PHARMACOGENOMICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 93. MEXICO PHARMACOGENOMICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 94. MEXICO PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 95. MEXICO PHARMACOGENOMICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 96. MEXICO PHARMACOGENOMICS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 97. MEXICO PHARMACOGENOMICS MARKET SIZE, BY SOFTWARE AND PLATFORMS, 2018-2030 (USD MILLION)
TABLE 98. MEXICO PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 99. MEXICO PHARMACOGENOMICS MARKET SIZE, BY MICROARRAY, 2018-2030 (USD MILLION)
TABLE 100. MEXICO PHARMACOGENOMICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2030 (USD MILLION)
TABLE 101. MEXICO PHARMACOGENOMICS MARKET SIZE, BY SEQUENCING, 2018-2030 (USD MILLION)
TABLE 102. MEXICO PHARMACOGENOMICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 103. MEXICO PHARMACOGENOMICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 104. MEXICO PHARMACOGENOMICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 105. MEXICO PHARMACOGENOMICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 106. BRAZIL PHARMACOGENOMICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 107. BRAZIL PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 108. BRAZIL PHARMACOGENOMICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL PHARMACOGENOMICS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL PHARMACOGENOMICS MARKET SIZE, BY SOFTWARE AND PLATFORMS, 2018-2030 (USD MILLION)
TABLE 111. BRAZIL PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 112. BRAZIL PHARMACOGENOMICS MARKET SIZE, BY MICROARRAY, 2018-2030 (USD MILLION)
TABLE 113. BRAZIL PHARMACOGENOMICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2030 (USD MILLION)
TABLE 114. BRAZIL PHARMACOGENOMICS MARKET SIZE, BY SEQUENCING, 2018-2030 (USD MILLION)
TABLE 115. BRAZIL PHARMACOGENOMICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL PHARMACOGENOMICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL PHARMACOGENOMICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 118. BRAZIL PHARMACOGENOMICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 119. ARGENTINA PHARMACOGENOMICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 120. ARGENTINA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 121. ARGENTINA PHARMACOGENOMICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 122. ARGENTINA PHARMACOGENOMICS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 123. ARGENTINA PHARMACOGENOMICS MARKET SIZE, BY SOFTWARE AND PLATFORMS, 2018-2030 (USD MILLION)
TABLE 124. ARGENTINA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 125. ARGENTINA PHARMACOGENOMICS MARKET SIZE, BY MICROARRAY, 2018-2030 (USD MILLION)
TABLE 126. ARGENTINA PHARMACOGENOMICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2030 (USD MILLION)
TABLE 127. ARGENTINA PHARMACOGENOMICS MARKET SIZE, BY SEQUENCING, 2018-2030 (USD MILLION)
TABLE 128. ARGENTINA PHARMACOGENOMICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 129. ARGENTINA PHARMACOGENOMICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 130. ARGENTINA PHARMACOGENOMICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 131. ARGENTINA PHARMACOGENOMICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY SOFTWARE AND PLATFORMS, 2018-2030 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY MICROARRAY, 2018-2030 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2030 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY SEQUENCING, 2018-2030 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 146. UNITED KINGDOM PHARMACOGENOMICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 147. UNITED KINGDOM PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 148. UNITED KINGDOM PHARMACOGENOMICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 149. UNITED KINGDOM PHARMACOGENOMICS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 150. UNITED KINGDOM PHARMACOGENOMICS MARKET SIZE, BY SOFTWARE AND PLATFORMS, 2018-2030 (USD MILLION)
TABLE 151. UNITED KINGDOM PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 152. UNITED KINGDOM PHARMACOGENOMICS MARKET SIZE, BY MICROARRAY, 2018-2030 (USD MILLION)
TABLE 153. UNITED KINGDOM PHARMACOGENOMICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2030 (USD MILLION)
TABLE 154. UNITED KINGDOM PHARMACOGENOMICS MARKET SIZE, BY SEQUENCING, 2018-2030 (USD MILLION)
TABLE 155. UNITED KINGDOM PHARMACOGENOMICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 156. UNITED KINGDOM PHARMACOGENOMICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 157. UNITED KINGDOM PHARMACOGENOMICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 158. UNITED KINGDOM PHARMACOGENOMICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 159. GERMANY PHARMACOGENOMICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 160. GERMANY PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 161. GERMANY PHARMACOGENOMICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 162. GERMANY PHARMACOGENOMICS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 163. GERMANY PHARMACOGENOMICS MARKET SIZE, BY SOFTWARE AND PLATFORMS, 2018-2030 (USD MILLION)
TABLE 164. GERMANY PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 165. GERMANY PHARMACOGENOMICS MARKET SIZE, BY MICROARRAY, 2018-2030 (USD MILLION)
TABLE 166. GERMANY PHARMACOGENOMICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2030 (USD MILLION)
TABLE 167. GERMANY PHARMACOGENOMICS MARKET SIZE, BY SEQUENCING, 2018-2030 (USD MILLION)
TABLE 168. GERMANY PHARMACOGENOMICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 169. GERMANY PHARMACOGENOMICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 170. GERMANY PHARMACOGENOMICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 171. GERMANY PHARMACOGENOMICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 172. FRANCE PHARMACOGENOMICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 173. FRANCE PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 174. FRANCE PHARMACOGENOMICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 175. FRANCE PHARMACOGENOMICS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 176. FRANCE PHARMACOGENOMICS MARKET SIZE, BY SOFTWARE AND PLATFORMS, 2018-2030 (USD MILLION)
TABLE 177. FRANCE PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 178. FRANCE PHARMACOGENOMICS MARKET SIZE, BY MICROARRAY, 2018-2030 (USD MILLION)
TABLE 179. FRANCE PHARMACOGENOMICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2030 (USD MILLION)
TABLE 180. FRANCE PHARMACOGENOMICS MARKET SIZE, BY SEQUENCING, 2018-2030 (USD MILLION)
TABLE 181. FRANCE PHARMACOGENOMICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 182. FRANCE PHARMACOGENOMICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 183. FRANCE PHARMACOGENOMICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 184. FRANCE PHARMACOGENOMICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 185. RUSSIA PHARMACOGENOMICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 186. RUSSIA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 187. RUSSIA PHARMACOGENOMICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 188. RUSSIA PHARMACOGENOMICS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 189. RUSSIA PHARMACOGENOMICS MARKET SIZE, BY SOFTWARE AND PLATFORMS, 2018-2030 (USD MILLION)
TABLE 190. RUSSIA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 191. RUSSIA PHARMACOGENOMICS MARKET SIZE, BY MICROARRAY, 2018-2030 (USD MILLION)
TABLE 192. RUSSIA PHARMACOGENOMICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2030 (USD MILLION)
TABLE 193. RUSSIA PHARMACOGENOMICS MARKET SIZE, BY SEQUENCING, 2018-2030 (USD MILLION)
TABLE 194. RUSSIA PHARMACOGENOMICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 195. RUSSIA PHARMACOGENOMICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 196. RUSSIA PHARMACOGENOMICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 197. RUSSIA PHARMACOGENOMICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 198. ITALY PHARMACOGENOMICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 199. ITALY PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 200. ITALY PHARMACOGENOMICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 201. ITALY PHARMACOGENOMICS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 202. ITALY PHARMACOGENOMICS MARKET SIZE, BY SOFTWARE AND PLATFORMS, 2018-2030 (USD MILLION)
TABLE 203. ITALY PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 204. ITALY PHARMACOGENOMICS MARKET SIZE, BY MICROARRAY, 2018-2030 (USD MILLION)
TABLE 205. ITALY PHARMACOGENOMICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2030 (USD MILLION)
TABLE 206. ITALY PHARMACOGENOMICS MARKET SIZE, BY SEQUENCING, 2018-2030 (USD MILLION)
TABLE 207. ITALY PHARMACOGENOMICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 208. ITALY PHARMACOGENOMICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 209. ITALY PHARMACOGENOMICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 210. ITALY PHARMACOGENOMICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 211. SPAIN PHARMACOGENOMICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 212. SPAIN PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 213. SPAIN PHARMACOGENOMICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 214. SPAIN PHARMACOGENOMICS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 215. SPAIN PHARMACOGENOMICS MARKET SIZE, BY SOFTWARE AND PLATFORMS, 2018-2030 (USD MILLION)
TABLE 216. SPAIN PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 217. SPAIN PHARMACOGENOMICS MARKET SIZE, BY MICROARRAY, 2018-2030 (USD MILLION)
TABLE 218. SPAIN PHARMACOGENOMICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2030 (USD MILLION)
TABLE 219. SPAIN PHARMACOGENOMICS MARKET SIZE, BY SEQUENCING, 2018-2030 (USD MILLION)
TABLE 220. SPAIN PHARMACOGENOMICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 221. SPAIN PHARMACOGENOMICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 222. SPAIN PHARMACOGENOMICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 223. SPAIN PHARMACOGENOMICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 224. UNITED ARAB EMIRATES PHARMACOGENOMICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 225. UNITED ARAB EMIRATES PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 226. UNITED ARAB EMIRATES PHARMACOGENOMICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 227. UNITED ARAB EMIRATES PHARMACOGENOMICS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 228. UNITED ARAB EMIRATES PHARMACOGENOMICS MARKET SIZE, BY SOFTWARE AND PLATFORMS, 2018-2030 (USD MILLION)
TABLE 229. UNITED ARAB EMIRATES PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 230. UNITED ARAB EMIRATES PHARMACOGENOMICS MARKET SIZE, BY MICROARRAY, 2018-2030 (USD MILLION)
TABLE 231. UNITED ARAB EMIRATES PHARMACOGENOMICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2030 (USD MILLION)
TABLE 232. UNITED ARAB EMIRATES PHARMACOGENOMICS MARKET SIZE, BY SEQUENCING, 2018-2030 (USD MILLION)
TABLE 233. UNITED ARAB EMIRATES PHARMACOGENOMICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 234. UNITED ARAB EMIRATES PHARMACOGENOMICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 235. UNITED ARAB EMIRATES PHARMACOGENOMICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 236. UNITED ARAB EMIRATES PHARMACOGENOMICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 237. SAUDI ARABIA PHARMACOGENOMICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 238. SAUDI ARABIA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 239. SAUDI ARABIA PHARMACOGENOMICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 240. SAUDI ARABIA PHARMACOGENOMICS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 241. SAUDI ARABIA PHARMACOGENOMICS MARKET SIZE, BY SOFTWARE AND PLATFORMS, 2018-2030 (USD MILLION)
TABLE 242. SAUDI ARABIA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 243. SAUDI ARABIA PHARMACOGENOMICS MARKET SIZE, BY MICROARRAY, 2018-2030 (USD MILLION)
TABLE 244. SAUDI ARABIA PHARMACOGENOMICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2030 (USD MILLION)
TABLE 245. SAUDI ARABIA PHARMACOGENOMICS MARKET SIZE, BY SEQUENCING, 2018-2030 (USD MILLION)
TABLE 246. SAUDI ARABIA PHARMACOGENOMICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 247. SAUDI ARABIA PHARMACOGENOMICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 248. SAUDI ARABIA PHARMACOGENOMICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 249. SAUDI ARABIA PHARMACOGENOMICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 250. SOUTH AFRICA PHARMACOGENOMICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 251. SOUTH AFRICA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 252. SOUTH AFRICA PHARMACOGENOMICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 253. SOUTH AFRICA PHARMACOGENOMICS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 254. SOUTH AFRICA PHARMACOGENOMICS MARKET SIZE, BY SOFTWARE AND PLATFORMS, 2018-2030 (USD MILLION)
TABLE 255. SOUTH AFRICA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 256. SOUTH AFRICA PHARMACOGENOMICS MARKET SIZE, BY MICROARRAY, 2018-2030 (USD MILLION)
TABLE 257. SOUTH AFRICA PHARMACOGENOMICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2030 (USD MILLION)
TABLE 258. SOUTH AFRICA PHARMACOGENOMICS MARKET SIZE, BY SEQUENCING, 2018-2030 (USD MILLION)
TABLE 259. SOUTH AFRICA PHARMACOGENOMICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 260. SOUTH AFRICA PHARMACOGENOMICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 261. SOUTH AFRICA PHARMACOGENOMICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 262. SOUTH AFRICA PHARMACOGENOMICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 263. DENMARK PHARMACOGENOMICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 264. DENMARK PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 265. DENMARK PHARMACOGENOMICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 266. DENMARK PHARMACOGENOMICS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 267. DENMARK PHARMACOGENOMICS MARKET SIZE, BY SOFTWARE AND PLATFORMS, 2018-2030 (USD MILLION)
TABLE 268. DENMARK PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 269. DENMARK PHARMACOGENOMICS MARKET SIZE, BY MICROARRAY, 2018-2030 (USD MILLION)
TABLE 270. DENMARK PHARMACOGENOMICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2030 (USD MILLION)
TABLE 271. DENMARK PHARMACOGENOMICS MARKET SIZE, BY SEQUENCING, 2018-2030 (USD MILLION)
TABLE 272. DENMARK PHARMACOGENOMICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 273. DENMARK PHARMACOGENOMICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 274. DENMARK PHARMACOGENOMICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 275. DENMARK PHARMACOGENOMICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 276. NETHERLANDS PHARMACOGENOMICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 277. NETHERLANDS PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 278. NETHERLANDS PHARMACOGENOMICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 279. NETHERLANDS PHARMACOGENOMICS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 280. NETHERLANDS PHARMACOGENOMICS MARKET SIZE, BY SOFTWARE AND PLATFORMS, 2018-2030 (USD MILLION)
TABLE 281. NETHERLANDS PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 282. NETHERLANDS PHARMACOGENOMICS MARKET SIZE, BY MICROARRAY, 2018-2030 (USD MILLION)
TABLE 283. NETHERLANDS PHARMACOGENOMICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2030 (USD MILLION)
TABLE 284. NETHERLANDS PHARMACOGENOMICS MARKET SIZE, BY SEQUENCING, 2018-2030 (USD MILLION)
TABLE 285. NETHERLANDS PHARMACOGENOMICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 286. NETHERLANDS PHARMACOGENOMICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 287. NETHERLANDS PHARMACOGENOMICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 288. NETHERLANDS PHARMACOGENOMICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 289. QATAR PHARMACOGENOMICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 290. QATAR PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 291. QATAR PHARMACOGENOMICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 292. QATAR PHARMACOGENOMICS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 293. QATAR PHARMACOGENOMICS MARKET SIZE, BY SOFTWARE AND PLATFORMS, 2018-2030 (USD MILLION)
TABLE 294. QATAR PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 295. QATAR PHARMACOGENOMICS MARKET SIZE, BY MICROARRAY, 2018-2030 (USD MILLION)
TABLE 296. QATAR PHARMACOGENOMICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2030 (USD MILLION)
TABLE 297. QATAR PHARMACOGENOMICS MARKET SIZE, BY SEQUENCING, 2018-2030 (USD MILLION)
TABLE 298. QATAR PHARMACOGENOMICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 299. QATAR PHARMACOGENOMICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 300. QATAR PHARMACOGENOMICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 301. QATAR PHARMACOGENOMICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 302. FINLAND PHARMACOGENOMICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 303. FINLAND PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 304. FINLAND PHARMACOGENOMICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 305. FINLAND PHARMACOGENOMICS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 306. FINLAND PHARMACOGENOMICS MARKET SIZE, BY SOFTWARE AND PLATFORMS, 2018-2030 (USD MILLION)
TABLE 307. FINLAND PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 308. FINLAND PHARMACOGENOMICS MARKET SIZE, BY MICROARRAY, 2018-2030 (USD MILLION)
TABLE 309. FINLAND PHARMACOGENOMICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2030 (USD MILLION)
TABLE 310. FINLAND PHARMACOGENOMICS MARKET SIZE, BY SEQUENCING, 2018-2030 (USD MILLION)
TABLE 311. FINLAND PHARMACOGENOMICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 312. FINLAND PHARMACOGENOMICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 313. FINLAND PHARMACOGENOMICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 314. FINLAND PHARMACOGENOMICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 315. SWEDEN PHARMACOGENOMICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 316. SWEDEN PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 317. SWEDEN PHARMACOGENOMICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 318. SWEDEN PHARMACOGENOMICS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 319. SWEDEN PHARMACOGENOMICS MARKET SIZE, BY SOFTWARE AND PLATFORMS, 2018-2030 (USD MILLION)
TABLE 320. SWEDEN PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 321. SWEDEN PHARMACOGENOMICS MARKET SIZE, BY MICROARRAY, 2018-2030 (USD MILLION)
TABLE 322. SWEDEN PHARMACOGENOMICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2030 (USD MILLION)
TABLE 323. SWEDEN PHARMACOGENOMICS MARKET SIZE, BY SEQUENCING, 2018-2030 (USD MILLION)
TABLE 324. SWEDEN PHARMACOGENOMICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 325. SWEDEN PHARMACOGENOMICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 326. SWEDEN PHARMACOGENOMICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 327. SWEDEN PHARMACOGENOMICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 328. NIGERIA PHARMACOGENOMICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 329. NIGERIA PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 330. NIGERIA PHARMACOGENOMICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 331. NIGERIA PHARMACOGENOMICS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 332. NIGERIA PHARMACOGENOMICS MARKET SIZE, BY SOFTWARE AND PLATFORMS, 2018-2030 (USD MILLION)
TABLE 333. NIGERIA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 334. NIGERIA PHARMACOGENOMICS MARKET SIZE, BY MICROARRAY, 2018-2030 (USD MILLION)
TABLE 335. NIGERIA PHARMACOGENOMICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2030 (USD MILLION)
TABLE 336. NIGERIA PHARMACOGENOMICS MARKET SIZE, BY SEQUENCING, 2018-2030 (USD MILLION)
TABLE 337. NIGERIA PHARMACOGENOMICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 338. NIGERIA PHARMACOGENOMICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 339. NIGERIA PHARMACOGENOMICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 340. NIGERIA PHARMACOGENOMICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 341. EGYPT PHARMACOGENOMICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 342. EGYPT PHARMACOGENOMICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 343. EGYPT PHARMACOGENOMICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 344. EGYPT PHARMACOGENOMICS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 345. EGYPT PHARMACOGENOMICS MARKET SIZE, BY SOFTWARE AND PLATFORMS, 2018-2030 (USD MILLION)
TABLE 346. EGYPT PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 347. EGYPT PHARMACOGENOMICS MARKET SIZE, BY MICROARRAY, 2018-2030 (USD MILLION)
TABLE 348. EGYPT PHARMACOGENOMICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2030 (USD MILLION)
TABLE 349. EGYPT PHARMACOGENOMICS MARKET SIZE, BY SEQUENCING, 2018-2030 (USD MILLION)
TABLE 350. EGYPT PHARMACOGENOMICS MARKET SIZE, BY END USER, 2018-2030

Companies Mentioned

The companies profiled in this Pharmacogenomics market report include:
  • Thermo Fisher Scientific Inc.
  • Illumina, Inc.
  • F. Hoffmann-La Roche Ltd
  • QIAGEN N.V.
  • PerkinElmer, Inc.
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • Myriad Genetics, Inc.
  • Invitae Corporation
  • Natera, Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages198
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 4.98 Billion
Forecasted Market Value ( USD ) by 2030 $ 8.21 Billion
Compound Annual Growth Rate10.5%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Pharmacogenomics Technology Market Size, Share & Trends Analysis Report by Therapeutic Area (Neurological Disorders, Cardiovascular Disease), Technology (PCR, in-situ Hybridization), Region, with Growth Forecasts, 2025-2030 - Product Image

Pharmacogenomics Technology Market Size, Share & Trends Analysis Report by Therapeutic Area (Neurological Disorders, Cardiovascular Disease), Technology (PCR, in-situ Hybridization), Region, with Growth Forecasts, 2025-2030

  • Report
  • 100 Pages
  • Global
From
Pharmacogenomics - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Pharmacogenomics - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Report
  • 150 Pages
  • Global
From
Pharmacogenomics Market Report by Technology, Application, End User, and Region 2024-2032 - Product Image

Pharmacogenomics Market Report by Technology, Application, End User, and Region 2024-2032

  • Report
  • 136 Pages
  • Global
From
Pharmacogenomics Technology - Global Strategic Business Report - Product Image

Pharmacogenomics Technology - Global Strategic Business Report

  • Report
  • 72 Pages
  • Global
From
Pharmacogenomics Technology Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2020-2030F - Product Image

Pharmacogenomics Technology Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2020-2030F

  • Report
  • 180 Pages
  • Global
From

About the Pharmacogenomics Market

Pharmacogenomics is a field of genomics that studies the relationship between an individual's genetic makeup and their response to drugs. It is used to develop personalized medicine, which is tailored to an individual's genetic profile. This field of genomics has the potential to revolutionize the way drugs are developed and prescribed, as it can help to identify which drugs are most effective for a particular patient. It can also help to reduce the risk of adverse drug reactions, as well as reduce the cost of drug development. Pharmacogenomics is a rapidly growing field, with many companies investing in research and development. Examples of companies in the market include 23andMe, Genomics England, and Illumina. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.